Zu den Deals
Gesundheitswesen

Building a leading one-stop ambulatory cancer center

SIAMH has successfully registered the offer document, launched an IPO and raised US$19.5 million.

SIAMH is a one-stop outpatient diagnostics and treatment center for cancer, neurogenerative and cardiovascular diseases in Singapore.

Oaklins’ team in Singapore acted as sponsor, issue manager, underwriter and placement agent in this transaction.

Sprechen Sie mit dem Deal-Team

Mark Liew

Partner
Singapur, Singapur
Oaklins PrimePartners

Relevante Transaktionen

Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
Gesundheitswesen

Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland

LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.

Weitere Informationen
EuroHospital Varna has been acquired by Intermedica Group
Gesundheitswesen

EuroHospital Varna has been acquired by Intermedica Group

EuroHospital Varna has been acquired by Intermedica Group, allowing the business to continue to grow and deliver high-quality healthcare services to its patients. Through the transaction, Intermedica Group expands its healthcare presence and intends to build a new model of integrated personalized care focused on preventive, holistic and digital medicine.

Weitere Informationen
Olyos Group has acquired a controlling stake in NewScience
Gesundheitswesen

Olyos Group has acquired a controlling stake in NewScience

Olyos Group has acquired a controlling stake in NewScience from its founders through a transaction structured in two stages, with the strategic objective of ultimately acquiring 100% of the company. The transaction forms part of NewScience’s international growth strategy and a gradual cash-out process for the founder, who intends to complete a full exit. Olyos intends to retain the management team through a put and call option mechanism and an earn-out linked to NewScience’s 2025 EBITDA.

Weitere Informationen